Vitae Pharmaceuticals (VTAE) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results
May 10, 2016 4:01 PM EDTProof-of-concept data for VTP-38543 expected in the second half of 2016
Conference call scheduled for 4:30 p.m. EDT today
FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended March 31, 2016.
Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, The highlight of the first quarter was the positive top-line results from Vitaes Phase 2a proof-of-concept clinical trial of VTP-43742, our wholly owned, first-in-class RORt inhibitor, in... More
